PsychU

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2023-03-22 12:00 - 13:00 (America/North_Dakota/New_Salem)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Iowa, Illinois, Kansas, Minnesota, Missouri, North Dakota, South Dakota, and Wisconsin.

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Steven Stoner, PharmD
Associate Dean for Student Affairs/Clinical Professor, University of Missouri-Kansas City School of Pharmacy

More

Steven Stoner, PharmD, BCPP, is Board Certified in Psychiatric Pharmacy. He is the associate dean of Student Affairs and a Clinical Professor at the UMKC School of Pharmacy. He received his PharmD from the University of Nebraska College of Pharmacy. Dr. Stoner completed a postdoctoral residency in psychiatric pharmacy practice and administration and a fellowship at Western Missouri Mental Health Center in Kansas City, Missouri.

Maria Perez, PharmD, AAHIVP
Medical Science Liaison – Digital Therapeutics

Speaker Steven Stoner, PharmD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Maria Perez, PharmD, AAHIVP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2023-03-20 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Indiana, Kentucky, Michigan, and Ohio.

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Gwendolyn Stockton, PharmD, BCPP
Medical Science Liaison

Alex Matushek, PharmD, MBA
Medical Science Liaison

Speakers Gwendolyn Stockton, PharmD, BCPP and Alex Matushek, PharmD, MBA are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2023-03-15 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in North Carolina and South Carolina.

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Miranda Fisher, PhD
Medical Science Liaison

Amica Simmons-Yon, PharmD, PhD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Speakers Miranda Fisher, PhD and Amica Simmons-Yon, PharmD, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2023-03-14 12:00 - 13:00 (America/Denver)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Alaska; Arizona; Colorado; Idaho; Montana; Nevada; New Mexico; Oregon; El Paso, Texas; Utah, Washington, and Wyoming.

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Jessie Chambers, PhD
Medical Science Liaison

Simon Kim, PharmD
Medical Science Liaison

Speakers Jessie Chambers, PhD and Simon Kim, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
2023-03-08 12:00 - 13:00 (America/Los_Angeles)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Live Event for PsychU Members in Alaska, Oregon, and Washington.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health

Simon Kim, PharmD
Medical Science Liaison

Speaker Chet Robachinski, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
2023-02-28 18:30 - 21:00 (America/New_York) | La Terrazza, 291 South Main Street, New City, NY, 10956, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in Bronx, Westchester, and Rockland county, NY.
Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit: risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.

In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.

Venue

Featuring

Jehan Marino, PharmD, BCPP
Medical Science Director

Brijesh Patel, PharmD
Medical Science Liaison

Speakers Jehan Marino, PharmD, BCPP and Brijesh Patel, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Addressing Unresolved Symptoms of Major Depressive Disorder (MDD): The Importance of Norepinephrine, Serotonin, and Dopamine Modulation
2023-02-16 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Join the PsychU community for this exciting webinar featuring experts in psychiatry, Joseph Goldberg and Vladimir Maletic, as they describe aspects of pathophysiology in major depressive disorder. An emphasis will be placed on the role of several monoamine neurotransmitter systems including norepinephrine, serotonin, and dopamine. Drs. Goldberg and Maletic will highlight the burden of disease in depression and discuss current guideline recommendations on MDD treatments, including considerations for augmentation strategies. Guided by moderator, Rachel Self, they will discuss the current psychiatry treatment landscape and provide context around recent publications raising questions regarding depression pathophysiology and the monoamine model.
Join us for an exciting and informative dialogue on the pathophysiology of depression and treatment recommendations for those with unresolved symptoms!

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Vladimir Maletic, MD
Serves as Clinical Professor, Psychiatry/Behavioral Science, University of South Carolina School of Medicine Greenville, SC

More

Vladimir Maletic, MD serves as Clinical Professor, Psychiatry/Behavioral Science, School of Medicine Greenville, SC and has been rated as Best Doctors of the America Registry and Psychiatrist of the year. Dr. Maletic received the Upjohn Achievement Award and Student Council teaching award and faculty award for teaching achievement. He also has received the Medical School Award for Academic Achievement.

Rachel Self, PhD, MS (OPDC)
Medical Science Director, Neuroscience Field Medical Affairs

More

Rachel Self, PhD, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs, neuroscientist, & wellness advocate.

Speakers Joseph Goldberg, MD and Vladimir Maletic, MD, MS are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Rachel Self, PhD, MS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2023-02-14 15:00 - 16:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Maryland, Washington, DC, and Virginia.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Speaker Dennis Sholler, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Pharmacokinetics, Plasma Concentrations & (Their) Clinical Relevance
2023-01-26 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Pharmacokinetics refers to the study of how drugs are processed by the body. These processes play an important role in mental health treatments, and can vary due to several factors, ultimately impacting treatment of mental health. In this webinar, we will first provide an overview of pharmacokinetics and pharmacodynamics. Then, we will discuss the differences between pharmacokinetics based on different medication formulations, including the differences between oral and long-acting injectable formulations. Finally, the importance of pharmacokinetics and plasma concentration monitoring will be discussed as it relates to the clinical setting.

Featuring

Stephen R. Saklad, PharmD, BCPP
Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio; Clinical Professor, UTHSCSA, School of Medicine, Pharmacotherapy Education & Research Center, The University of Texas at Austin College of Pharmacy; and Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services

More

Stephen Saklad, PharmD is a Clinical Professor of Pharmacotherapy and Adjoint Professor, School of Medicine, and Director, Psychiatric Pharmacy Program at the University of Texas, and a Clinical Pharmacologist for the San Antonio State Hospital, Texas Department of State Health Services. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH. Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP; now the American Association of Psychiatric Pharmacists, AAPP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize, and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee, was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, Treasurer of the CPNP Foundation, and a member of the CPNP Business Development Committee. He is the Director of The University of Texas Psychiatric Pharmacy Program

Dennis Pabis, PharmD, BCPP (OPDC)
Senior Medical Science Liaison

Speaker Stephen R. Saklad, PharmD, BCPP is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Dennis Pabis, PharmD, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
2023-01-25 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Live Event for PsychU members in Connecticut, New Jersey, and New York City, NY.
Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit: risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.
In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.

Featuring

Jehan Marino, PharmD, BCPP
Medical Science Director

Alyssa Weers, PharmD (OPDC)
Clinical & Scientific Liaison

Speakers Alyssa Weers PharmD and Jehan Marino PharmD, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - Management of Major Depressive Disorder: Breaking Through the Barriers
2023-01-18 19:00 - 21:00 (America/New_York) | Matteo’s, 300 W Jericho Turnpike, Huntington Station, NY, 11743, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in Long Island, Queens and Brooklyn, NY.
In this presentation, the objectives are to:

To understand that Major Depressive Disorder (MDD) is a serious illness leading to decreased overall patient health and quality of life
To investigate the effect of inadequate treatment response in MDD on patients and their families
To recognize predictors of and important considerations for inadequate treatment response in MDD, including the new DSM-5 specifier for anxious distress
To consider the importance of proactive treatment decisions

Venue

Featuring

Yadagiri Chepuru, MD, FAPA
Chief of Psychiatry, St. John's Riverside Hospital, Yonkers, NY

Jehan Marino, PharmD, BCPP
Medical Science Director

Erika Modh, PharmD, BCPS
Medical Science Liaison

Speaker Yadagiri Chepuru, MD, FAPA is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).Speakers Jehan Marino, PharmD, BCPP and Erika Modh, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
2023-01-11 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.
Objectives:

Review the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)
List the currently available treatment recommendations and guidelines for AAD treatment recommendations
Identify gaps with current treatment options, both pharmacologic and nonpharmacologic

Featuring

William Clay Jackson, MD, DipTh
Assistant Professor of Clinical Psychiatry & Family Medicine; University of TN College of Medicine

Bryan Archuleta, PharmD
Senior Long-Term Care Medical Science Liaison

Speaker W. Clay Jackson, MD, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Bryan Archuleta, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - All Hands On Deck In The Treatment Of Major Depressive Disorder (MDD): A Focus On Measurement-Based Care In Psychiatry & Primary Care
2022-12-14 18:00 - 20:00 (America/New_York) | Spanish Tavern, 103 McWhorter St A, Newark, NJ, 07105, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in New York and New Jersey.
Given the current state of affairs, primary care providers are increasingly treating patients with Major Depressive Disorder (MDD). During this panel presentation, Savatta Salvatore, MD; Michael Townsend, MA, LCSW; and C. Brendan Montano, MD, will be discussing the prevalence and burden of MDD within the Tri-State area (NY/NJ/CT), with an emphasis on New Jersey and the impact of COVID-19 on MDD. Additionally, the speakers will discuss barriers faced by primary care providers and include the perspectives and expertise from psychiatrists. Finally, the presenters will consider the potential role of measurement-based care, focusing on the strategies incorporated in their practices and discussing methods of collaboration.

Objectives:

Discuss the prevalence and burden of Major Depressive Disorder (MDD) locally and nationally, including the impact of COVID-19
Identify gaps between primary care and psychiatry within the treatment of MDD
Understand the potential role and importance of measurement-based care (MBC)
Consider methods of collaboration that may improve outcomes for patients with MDD

Venue

Featuring

Salvatore G. Savatta, MD
Chair of Psychiatry, Trinitas Regional Medical Center, Elizabeth, NJ

More

Dr. Salvatore G. Savatta received his Bachelor of Arts degree in Economics from New York University, graduated from New York University School of Medicine in 2001 and completed his M.S. in Biostatistics Clinical Research Methods at Columbia University’s Mailman School of Public Health in 2005. Dr. Savatta has previously served as Director of Inpatient Psychiatry at New York Methodist Hospital, Medical Director of TMS Centers of America and both Deputy Chair and Interim Chair of Psychiatry at Trinitas Regional Medical Center. He presently serves as Chair of Psychiatry at Trinitas and has done so since May of 2020.
Dr. Savatta completed his Psychiatry Residency at St. Vincent’s Catholic Medical Center and completed a Public Service Psychiatry Fellowship and a Forensic Psychiatry Fellowship at the University of Pittsburgh Medical Center – Western Psychiatric Institute and Clinic. Dr. Savatta is Board Certified in both Adult Psychiatry and Forensic Psychiatry.
He has tailored his clinical practice to focus on “difficult to treat” depression, and often includes the implementation of Neuromodulation techniques such as TMS, Esketamine, and Electroconvulsive Therapy (ECT) when clinically appropriate.

Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center

More

Mr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.

C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut

More

Brendan Montano, MD, is the owner and medical director of Montano Wellness, LLC, and director of and a principal investigator for CT Clinical Research, all in Cromwell, Connecticut. Dr Montano is also an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut, a clinical instructor at Springfield College in Springfield, Massachusetts, and a primary care section advisor online for PsychU. He earned his medical degree from Albany College in Albany, New York. He completed his residency in internal medicine at Saint Francis Hospital and Medical Center in Hartford, Connecticut. Dr Montano has served as a principal investigator for over 120 clinical trials to evaluate the safety and efficacy of novel therapeutics for indications such as attention-deficit/hyperactivity disorder, major depressive disorder, and many other psychiatric and neurologic conditions. He is an editorial board member of The Primary Care Companion for CNS Disorders.

Brijesh Patel, PharmD
Medical Science Liaison

Becky Wong, PharmD, MBA
Medical Science Director

Speakers Salvatore G. Savatta, MD; Michael Townsend, MA, LCSW; and C. Brendan Montano, MD, PC are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. Speakers Brijesh Patel, PharmD and Becky Wong, PharmD, MBA are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Agitation Associated with Alzheimer’s Dementia: Clinical, Humanistic, & Economic Burden
2022-12-14 11:00 - 12:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in D.C., Maryland, and Virginia.
In this presentation, topics of discussion are:

Clinical Burden
Humanistic Burden
Economic Burden
AAD is associated with substantial patient burden and long-term consequences

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Justin Wimmer, PharmD
Medical Science Liaison

Speakers Dennis Sholler, PhD and Justin Wimmer, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
2022-12-13 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

References

Dedic N, et al. Int J Mol Sci. 2021;22(24):13185. doi:10.3390/ijms222413185
Nair PC, et al. Mol Psychiatry. August 10, 2021. doi:10.1038/s41380-021-01250-7

Featuring

Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

More

Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.
He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

Jehan Marino, PharmD, BCPP
Medical Science Director

Speaker Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Jehan Marino, PharmD, BCPP is an employee for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Agitation Associated With Alzheimer’s Dementia Disease State Education: Disease State
2022-12-07 14:00 - 15:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Maryland, D.C., and Virginia.
In this presentation, topics of discussion are:
Alzheimer’s disease is highly prevalent, under-diagnosed, and predicted to increase significantly in the coming decades due to an aging population
Agitation is a common neuropsychiatric symptom of Alzheimer’s dementia and highly prevalent across patient settings and Alzheimer’s disease severities
The CMAI measures the frequency of manifestations of a broad range of agitated behaviors

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Justin Wimmer, PharmD
Medical Science Liaison

Speakers Dennis Sholler, PhD and Justin Wimmer, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics
2022-12-07 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Maryland, DC, Virginia, North Carolina, and South Carolina.
Bipolar I Disorder is characterized by mood episode recurrence, which impacts patient functioning and clinical outcomes. During our discussion, the speakers will discuss risk factors for mood recurrence including non-adherence. They will also discuss some management strategies including long acting injectables (LAIs) that may optimize patient outcomes.

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Amica Simmons-Yon, PharmD, PhD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Miranda Fisher, PhD
Medical Science Liaison

Speakers Dennis Sholler, PhD; Amica Simmons-Yon, PharmD, PhD; and Miranda Fisher, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

The Value Of Digital Therapeutics
2022-12-06 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Description: Digital therapeutics, a subset of digital health, are evidence-based, clinically validated software that combine health and technology to prevent, treat, or manage a medical condition. In this discussion, Dr. Madhukar Trivedi and Dr. Albert Mei will introduce the role of digital therapeutics in the current mental health landscape, describe the value that digital therapeutics may bring to patients, providers, payers, and health systems, and explore the regulation and reimbursement pathways in today’s digital health landscape.
Objectives:

Introduce the role of digital therapeutics in the current mental health landscape (obj 1)
Describe the value that digital therapeutics may bring to patients, providers, payers, and health systems (obj 2)
Explore regulation and reimbursement in today’s digital health landscape (obj 3)

Featuring

Madhukar Trivedi, MD
Director, Center For Depression Research & Clinical Care; Betty Jo Hay Distinguished Chair, Mental Health & Julie K. Hersh Chair, Depression Research & Clinical Care, UT Southwestern Medical Center

More

Dr. Trivedi is a psychiatrist and the Julie K. Hersh Chair in Depression Research and Clinical Care at UT Southwestern Medical Center in Dallas, TX. Dr. Trivedi completed his medical studies at Baroda Medical College in Baroda, India, and he completed his residency in Psychiatry at University General Hospital Medical College in Baroda, India, and Henry Ford Hospital in Detroit, Michigan. Dr. Trivedi is board certified by the American Board of Psychiatry and Neurology.

Albert Mei, PharmD
National Lead for Digital Innovation and Managed Ambulatory Care, Elevance Caremore

More

Albert Mei, PharmD, leads Digital Innovation and Managed Ambulatory Care at Elevance Caremore. Past managed care experiences include Sales and Account Management at Express Scripts/Evernorth, managed care residency with Navitus Health Solutions, and Quality and Patient Engagement at Aetna Medicare. His professional experience combined with Elevance’s vertical integration business model provides him with a 360-degree view on the healthcare payer landscape. He maintains a formulary philosophy that focuses on total cost of care and transparency to access. Additionally, he serves as an independent consultant to pharmaceutical manufacturers to help teams better engage customers and understand the underlying thoughts driving payer pharmacy teams.

Anna Basoff, PharmD
Managed Market Liaison

More

Anna Basoff, PharmD, is a Managed Market Liaison for Otsuka covering the US Northeast region. Dr. Basoff gained her Doctor of Pharmacy (PharmD) from Rutgers University. After graduating, she joined Horizon Blue Cross & Blue Shield of NJ as a clinical pharmacist where she worked on initiatives that included MTM (medication therapy management), digital health, and adherence. In the past, she has also worked as a pharmacist for Walgreens. She resides in NJ and continues to work with the Rutgers pharmacy students, as diplomat to their Academy of Managed Care Pharmacy (AMCP) student chapter.

Speaker Dr. Madhukar Trivedi is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Dr. Albert Mei was not compensated for their participation.Speaker Anna Basoff, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - Recognizing & Responding To Inadequately Treated Major Depressive Disorder (MDD)
2022-12-01 18:00 - 21:00 (America/Los_Angeles) | Anthony’s HomePort Everett, 1726 West Marine View Drive, Everett, WA, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in Washington.
In this presentation, the objectives are to:

Discuss the burden of MDD on the individual and society
Explore the negative impact of residual symptoms
Identify patient and treatment characteristics associated with a poor treatment response
Discuss strategies to optimize pharmacotherapy

Venue

Featuring

Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health

Simon Kim, PharmD
Medical Science Liaison

Speaker Chet Robachinski, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Joint Live Event - Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD)
2022-11-17 18:30 - 20:30 (America/Los_Angeles) | Larsen’s Grill – Oxnard, 590 Town Center Dr, Oxnard, CA, 93036, United States
Home

Events

About This Event

TEST VLE
There is a high prevalence of depression among patients with chronic kidney disease (CKD). This presentation will examine the clinical overlap between CKD and major depressive disorder (MDD) in symptomatology, behavioral and biological mechanisms, the impact of comorbid depression on CKD outcomes, and strategies for effective management of depression in CKD.

Venue

Featuring

Marla Dallal, PharmD, RPH
Clinical & Scientific Liaison (Nephrology)

More

Marla Dallal, PharmD, RPH is a Clinical & Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Elika Hefazi, PharmD, BCPP
Medical Science Liaison

Speakers Marla Dallal, PharmD, RPH and Elika Hefazi, PharmD, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Strategies to Optimize Patient Outcomes In Bipolar I Disorder
2022-11-15 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Connecticut, New Jersey, and New York.
Bipolar I Disorder is characterized by mood episode recurrence, which impacts patient functioning and clinical outcomes.1,2 During our discussion, Drs. Alyssa Weers and Jehan Marino, along with featured speaker, Dr. Joseph Goldberg, will discuss risk factors for mood recurrence including non-adherence. They will also discuss some management strategies including long acting injectables (LAIs) that may optimize patient outcomes.
Objectives:

Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorderReview management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

References:

Vaquez GH European Neuropsychopharmacology 2015; 25: 1501-1512
Kapczinski NS, et al. Expert Rev Neurother. 2017;17(3):277-285

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Jehan Marino, PharmD, BCPP
Medical Science Director

Alyssa Weers, PharmD (OPDC)
Clinical & Scientific Liaison

Speaker Joseph Goldberg, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Speakers Jehan Marino, PharmD, BCPP and Alyssa Weers, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Professional Mental Wellness: The Role Of Organizational & Occupational Health
2022-11-15 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Organizational and occupational health refers to any workplace health promotion activity or organizational policy designed to support healthy behavior in the workplace and to improve health outcomes.1 Usually, this includes physical health programs such as smoking cessation, health screenings, exercise initiatives, and vaccination clinics; however, many organizations have also been offering benefits that address contemporary workplace concerns like burnout and mental wellness. This is imperative as burnout and mental health concerns are common in the workplace. For example, recent data showed that as many as 77% of Americans have experienced burnout at their current job and 76% of full-time U.S. employees reported at least one symptom of a mental health condition in the past year.2,3 In this webinar, our speakers, Drs. Gaurava Agarwal and Sean Maloney, will review occupational and organizational health frameworks and principles that can be used to approach the growing problem of Burnout and help increase professional fulfillment.

References:

Marsh, G., et al. BMC Health Serv Res. 2018; 18: 565.
Workplace Burnout Survey. https://www2.deloitte.com/us/en/pages/about-deloitte/articles/burnout-survey.html Accessed September 2022.
2021 Mental Health at Work Report. https://www.mindsharepartners.org/mentalhealthatworkreport-2021. Accessed September 2022.

Featuring

Gaurava Agarwal, MD
Chief wellness executive, Northwestern Medicine
Director of Faculty Wellness, Northwestern University

More

Gaurava Agarwal, MD serves as the Major Depressive Disorder Section Advisor for PsychU. In addition, he is the Chief Wellness Executive, Northwestern Medicine Medical Groups; Associate Professor for the Department of Psychiatry and Behavioral Science and Medical Education, and Director of Medical Student Education in Psychiatry at Northwestern University’s Feinberg School of Medicine. He also is the Director of Physician Well-Being for Northwestern Medicine’s Medical Groups.

Sean Maloney, DO, MPH
Director, Occupational Health and Safety, Otsuka America Pharmaceutical, Inc.

More

Sean is the Director of Occupational Health and Safety for Otsuka America Pharmaceutical Inc. He is board certified in occupational medicine and completed his public health training in occupational health and safety. He has worked extensively in both the public and private sectors. Previously serving as an occupational health medical director for the largest healthcare system in New Jersey and a consultant in several unique industries including bio & life sciences, manufacturing, travel, tech & finance he approaches health and safety issues with a unique perspective. He is a fierce advocate for worker health and safety, supporting a holistic approach to employee wellbeing as a necessity for organizational success.

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Speakers Gaurava Agarwal, MD and Sean Maloney, DO, MPH are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Dennis Sholler, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Schizophrenia Treatment Goals & Shared Decision Making: A Practice-Based Learning Webinar
2022-11-09 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Join Dr. Correll and Dr. Schooler for a discussion on how to engage patients in their own treatment decisions, help them define their treatment goals, and address treatment barriers that are often associated with schizophrenia. Together, they will lead an engaging practice-based learning session designed to both teach shared decision-making strategies and then demonstrate how they put them into practice.

Featuring

Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

More

Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.
He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

Nina R. Schooler, PhD
Professor of Psychiatry and Behavioral Sciences; State University of New York Downstate Medical Center

More

Professor Schooler’s research focuses on treatment of psychosis and schizophrenia from its earliest identification to long-term course and outcomes. Her expertise spans both pharmacologic and psychosocial interventions. Other areas of research focus on tardive dyskinesia and the systematic assessments of side effects, assessment and treatment of negative symptoms and assessment of social and vocational function measures as key to understanding long-term outcomes for schizophrenia and psychosis. Most recently her work has turned to integrating measurement-based care into treatment programs for first episode psychosis.

Linzy Hendrickson, PhD
Senior Medical Science Liaison

Speakers Christoph Correll, MD and Nina R. Schooler, PhD are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.Speaker Linzy Hendrickson, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Early Intervention in Bipolar Disorder
2022-11-02 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
During this webinar, Dr. Goldberg and Dr. Tohen will discuss the importance of early intervention in patients diagnosed with bipolar disorder. Together they will share their clinical experience and discuss the implications of early versus delayed intervention and identify and explore potential treatment options in bipolar disorder.

Objectives:

Describe the implications of early versus later intervention in bipolar disorder
Explore suitable treatment options in bipolar disorder

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Mauricio Tohen, MD, DrPH, MBA
Chairman, Department of Psychiatry and Behavioral Sciences, Distinguished University Professor, University of New Mexico

More

Mauricio Tohen, MD, DrPH, MBA, is a University Distinguished Professor and Chairman of the Department of Psychiatry at the University of New Mexico Health Science Center, Albuquerque NM. From 2009 to 2013 he was a Professor of Psychiatry and The Krus Endowed Chair in Psychiatry at the University of Texas Health Science Center at San Antonio. Dr. Tohen received his medical degree from the National University of Mexico and his Doctor of Public Health degree in Epidemiology from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto, a clinical fellowship at McLean Hospital and Harvard Medical School, and a teaching fellowship in Epidemiology at the Harvard School of Public Health. From 1988 to 1997, Dr. Tohen was the Clinical Director of the Bipolar and Psychotic Disorders Program at McLean Hospital. From 1997 to 2008 he was a member of Lilly Research Laboratories reaching the senior-most scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as the Head of the Division of Mood and Anxiety Disorders. Dr. Tohen received a National Service Award in Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and Harvard University. He also received a FIRST award from the NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award and the Simon Bolivar Award from the American Psychiatric Association. In 2014 he was named by Thomson Reuter’s “The World’s Most Influential Scientific Minds, 2014”. Honorees were the scientists who ranked in the Top 1 percent by citations of their published work in 21 broad fields between 2002 and 2012.

Jason Carter, PharmD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Speakers Dr. Joseph Goldberg and Dr. Mauricio Tohen are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.Speaker Jason Carter, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Pathophysiology Of Agitation Associated With Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems
2022-10-26 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
Tau pathology and neurodegeneration in key prefrontal and subcortical brain regions may increase the risk of developing agitation in Alzheimer’s dementia.1 Specifically, agitation in Alzheimer’s dementia may reflect an imbalance between top-down executive control (i.e., hypoactivity in prefrontal regions) and bottom-up emotional drive (i.e., hyperactivity in subcortical regions including the amygdala).1 Moreover, agitation in Alzheimer’s dementia is associated with noradrenergic, serotonergic, and dopaminergic system dysfunction in brain circuits mediating the balance between executive control and emotional drive.2,3 In this webinar, the speakers will review the loss of behavior regulation and the role of the monoamine system in the pathophysiology of agitation associated with Alzheimer’s Dementia.
References
Rosenberg, P.B., et al. Mol Aspects Med. 2015; 43-44: 25-37.
Jacobs, H.I., et al. Mol Psychiatry. 2021; 26(3): 897-906.
3. Lanctôt, K.L., et al. J Neuropsychiatry Clin Neurosci. 2001; 13(1): 5-21.

Featuring

Laura Brennan, PhD (OPDC)
Medical Science Liaison

Miranda Fisher, PhD
Medical Science Liaison

Speakers Laura Brennan, PhD and Miranda Fisher, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

If you enjoyed today’s webinar, please be sure to check out our upcoming webinar, “Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia“.

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - Avoiding Burnout: Learning To Live & Work Well In Healthcare
2022-10-25 18:00 - 20:30 (America/New_York) | St. John’s Restaurant, 1278 MARKET ST., CHATTANOOGA, TN, 37402, United States
Home

Events

About This Event

TEST VLE
This is a Live Private Event for members of the Chattanooga Area Pharmacists Society.
In this presentation, the objectives are to:

Discuss the incidence and prevalence as well as define burnout and highlight some of the challenges with available data and definitions
Explore some of the biologic, social, and systems-related data pertaining to burnout
Review drivers of burnout as well as strategies to identify and address this challenge

Venue

Featuring

Jason Carter, PharmD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Rachel Self, PhD, MS (OPDC)
Medical Science Director, Neuroscience Field Medical Affairs

More

Rachel Self, PhD, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs, neuroscientist, & wellness advocate.

Speakers are employees of

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Live Event - Strategies to Optimize Patient Outcomes in Bipolar Disorder I
2022-10-24 18:30 - 20:30 (America/New_York) | Hyde Park, 247 North Shore Drive, Pittsburgh, PA, United States
Home

Events

About This Event

TEST VLE
This is a Live Private Event for members of the Pennsylvania Society of Physician Assistants – Pittsburgh Chapter.
Bipolar I Disorder is characterized by mood episode recurrence, which impacts patient functioning and clinical outcomes. During this presentation, speakers will discuss risk factors for mood recurrence including non-adherence. They will also discuss some management strategies including long acting injectables (LAIs) that may optimize patient outcomes.

Venue

Featuring

Marci Sturgeon-Rusiewicz, MS, LPC, NCC, CPSS, CPRP
Senior Manager of Recovery Services, Wesley Family Services

More

As the Senior Manager of Recovery and Resiliency for Wesley Family Services, Marci is a Licensed Professional Counselor (LPC) in the state of Pennsylvania, a Nationally Certified Counselor (NCC) and a Doctoral Candidate of Counseling Psychology. Her clinical work involves both assessment and psychotherapy to youth and young adults within a university counseling center as well as adults and older adults in a community behavioral healthcare setting. She has extensive experience in working with the diversities of individuals diagnosed with severe and persistent mental illness (SPMI) and severe emotional disturbance (SED) as a Psychiatric Rehabilitation Practitioner. Her oversight includes community Drop-In Centers serving both transition age and adults within Allegheny and Westmoreland Counties. She is the Clinical Manager of the First Episode Psychosis Program (ENGAGE) at Wesley Family Services. Marci has a background in program development within the community based behavioral healthcare setting. She is a holistic health practitioner who believes in the importance of maintaining a balance of mind and body for optimal wellness which she incorporates into both direct practice and her management style. Her work emphasizes a bio/psycho/social support system for youth and adults. She holds an undergraduate degree in art education from Carlow College and earned a Master of Science from Carlow University.

Katie Sulkowski, PharmD
Medical Science Liaison

Speaker Marci Sturgeon-Rusiewicz, MS, LPC, NCC, CPSS, CPRP is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Katie Sulkowski, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Live Event - Strategies To Optimize Patient Outcomes In Bipolar I Disorder
2022-10-19 18:30 - 20:30 (America/New_York) | Melt, 2880 Center Valley Parkway, Suite 624, Center Valley, PA, 18034, United States
Home

Events

About This Event

TEST VLE
This is a Live Private Event for members of Mid-Eastern Chapter of Pennsylvania Society of Health System Pharmacists (MEPSHP).
Bipolar I Disorder is characterized by mood episode recurrence, which impacts patient functioning and clinical outcomes. During this presentation, speakers will discuss risk factors for mood recurrence including non-adherence. They will also discuss some management strategies including long acting injectables (LAIs) that may optimize patient outcomes.

Venue

Featuring

Mark Tacelosky, PharmD
Senior Medical Science Liaison

Speaker Mark Tacelosky, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Management Of Major Depressive Disorder: Breaking Through The Barrier
2022-10-18 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

TEST VLE
This is a Virtual Event for PsychU members in Connecticut, New York, and New Jersey.
In this presentation, the objectives are to:
To understand that Major Depressive Disorder (MDD) is a serious illness leading to decreased overall patient health and quality of life
To investigate the effect of inadequate treatment response in MDD on patients and their families
To recognize predictors of and important considerations for inadequate treatment response in MDD, including the new DSM-5 specifier for anxious distress
To consider the importance of proactive treatment decisions

Featuring

George Alexopoulos, MD
DeWitt Wallace Distinguished Scholar, Founding Director, Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine

Jehan Marino, PharmD, BCPP
Medical Science Director

Becky Wong, PharmD, MBA
Medical Science Director

Speaker George Alexopoulos, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc.Speakers Jehan Marino, PharmD, BCPP and Becky Wong, PharmD, MBA are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Live Event - All Hands On Deck In The Treatment Of Major Depressive Disorder (MDD): A Focus On Measurement-Based Care In Psychiatry & Primary Care
2022-10-11 18:30 - 20:30 (America/New_York) | Ruth’s Chris Steak House – Manhattan, 148 West 51st Street, Manhattan, NY, 10019, United States
Home

Events

About This Event

TEST VLE
This is a Live Event for PsychU members in New York City, Westchster, and Long Island, NY.

Given the current state of affairs, primary care providers are increasingly treating patients with Major Depressive Disorder (MDD). During this panel presentation, our speakers will be discussing the prevalence and burden of MDD and the impact of COVID-19 on MDD. Additionally, they will discuss barriers faced by primary care providers and include the perspectives and expertise from psychiatrists. Finally, the presenters will consider the potential role of measurement-based care, focusing on the strategies incorporated in their practices and discussing methods of collaboration.

Objectives:

Discuss the prevalence and burden of Major Depressive Disorder (MDD) locally and nationally, including the impact of COVID-19
Identify gaps between primary care and psychiatry within treatment of MDD
Understand the potential role and importance of measurement-based care (MBC)
Consider methods of collaboration that may improve outcomes for patients with MDD

Venue

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Darcy Leon, PMHNP-BC
Psychiatric Nurse Practitioner

More

Darcy Leon is a psychiatric nurse practitioner currently working in outpatient psychiatry in Tarrytown, NY. She specializes in the treatment of mood disorders, traumatic brain injury, substance use disorders, and treatment-refractory psychiatric illnesses. Darcy also has a specific interest in psychodynamic psychopharmacology, which she employs to better connect patients with the ways their personal experiences interact with medication treatments.

C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut

More

Brendan Montano, MD, is the owner and medical director of Montano Wellness, LLC, and director of and a principal investigator for CT Clinical Research, all in Cromwell, Connecticut. Dr Montano is also an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut, a clinical instructor at Springfield College in Springfield, Massachusetts, and a primary care section advisor online for PsychU. He earned his medical degree from Albany College in Albany, New York. He completed his residency in internal medicine at Saint Francis Hospital and Medical Center in Hartford, Connecticut. Dr Montano has served as a principal investigator for over 120 clinical trials to evaluate the safety and efficacy of novel therapeutics for indications such as attention-deficit/hyperactivity disorder, major depressive disorder, and many other psychiatric and neurologic conditions. He is an editorial board member of The Primary Care Companion for CNS Disorders.

Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center

More

Mr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.

Jehan Marino, PharmD, BCPP
Medical Science Director

Erika Modh, PharmD, BCPS
Medical Science Liaison

Speakers Joseph Goldberg, MD; Darcy Leon, PMHNP-BC; C. Brendan Montano, MD, PC; and Michael Townsend, MA, LCSW are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.Speakers Jehan Marino, PharmD, BCPP and Erika Modh, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.
